<p>Kanawha Capital Management LLC 在第二季度购买了 CVS Health Corporation (NYSE:CVS - 免费报告) 的新股份，根据该公司最近向证券交易委员会 (SEC) 提交的 13F 表格。该基金购买了 3,128 股该药房运营商的股票，价值约为 216,000 美元。</p>
<ul>
<li>CVS Health 收益增长，股息保持强劲</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也调整了对该公司的持股。先锋集团 (Vanguard Group Inc.) 在第一季度将其在 CVS Health 的持股增加了 0.8%。先锋集团目前拥有 118,335,394 股该药房运营商的股票，价值 80.17223 亿美元，在此期间又增持了 969,027 股。道奇与考克斯 (Dodge &amp; Cox) 在第一季度将其在 CVS Health 的持股增加了 4.8%。道奇与考克斯目前拥有 73,459,122 股该药房运营商的股票，价值 49.76856 亿美元，在上个季度又购买了 3,353,223 股。景顺 (Invesco Ltd.) 在第一季度将其在 CVS Health 的持股增加了 13.2%。景顺目前拥有 20,413,853 股该药房运营商的股票，价值 13.83039 亿美元，在上个季度又购买了 2,375,764 股。普莱斯·T·罗威 (Price T Rowe Associates Inc. MD) 在第一季度将其在 CVS Health 的持股增加了 14.5%。普莱斯·T·罗威目前拥有 15,309,289 股该药房运营商的股票，价值 10.37205 亿美元，在上个季度又购买了 1,942,886 股。最后，查尔斯·施瓦布投资管理公司 (Charles Schwab Investment Management Inc.) 在第一季度将其在 CVS Health 的持股增加了 5.6%。查尔斯·施瓦布投资管理公司目前拥有 13,647,873 股该药房运营商的股票，价值 9.24643 亿美元，在上个季度又购买了 728,924 股。机构投资者和对冲基金持有该公司 80.66% 的股份。</p>
<h2>CVS Health 股价表现</h2>
<p>CVS Health 股票周五开盘价为 82.64 美元。该公司的 50 日移动平均价格为 74.00 美元，200 日移动平均价格为 68.12 美元。该公司的流动比率为 0.80，速动比率为 0.62，债务与股本比率为 0.74。该股票的市值为 1048.1 亿美元，市盈率为 23.08，市盈增长比率为 0.91，贝塔值为 0.60。CVS Health Corporation 的 52 周低点为 43.56 美元，52 周高点为 82.88 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 05/12 - 05/16</li>
</ul>
<p>CVS Health (NYSE:CVS - 获取免费报告) 最近在 7 月 31 日星期四发布了季度财报。该药房运营商报告每股收益 (EPS) 为 1.81 美元，超出市场共识预期的 1.46 美元，超出 0.35 美元。该公司本季度的收入为 989.2 亿美元，而市场共识预期为 948.7 亿美元。CVS Health 的股本回报率为 10.51%，净利润率为 1.17%。该公司本季度的收入较去年同期增长了 8.4%。在去年同期，该公司每股收益为 1.83 美元。CVS Health 将其 2025 财年的指引设定为 6.300-6.400 每股收益。作为一个整体，卖方分析师预计 CVS Health Corporation 本财年将发布 5.89 每股收益。</p>
<h2>CVS Health 宣布分红</h2>
<p>该公司还最近披露了季度分红，将于 11 月 3 日星期一支付。10 月 23 日星期四的股东将获得每股 0.665 美元的分红。这代表着每年 2.66 美元的分红和 3.2% 的收益率。除息日为 10 月 23 日星期四。CVS Health 的派息比率目前为 74.30%。</p>
<h2>CVS Health 内部交易</h2>
<ul>
<li>现在是买入诺和诺德股票的时机吗？</li>
</ul>
<p>在其他 CVS Health 的新闻中，董事安妮·A·芬纽肯 (Anne A. Finucane) 在 8 月 20 日星期三出售了 7,500 股该公司的股票。该股票以平均价格 71.02 美元出售，总交易额为 532,650.00 美元。出售后，该董事在公司中持有 22,156 股，价值约为 1,573,519.12 美元。此次交易使其持股减少了 25.29%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有该公司 1.22% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票研究分析师最近对该股票发表了看法。扎克斯研究 (Zacks Research) 在 9 月 8 日星期一的研究报告中将 CVS Health 的股票评级从 “强买” 下调至 “持有”。罗伯特·W·贝尔德 (Robert W. Baird) 在 8 月 14 日星期四的研究报告中将 CVS Health 的股票评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标价从 71.00 美元上调至 82.00 美元。高盛集团 (Goldman Sachs Group) 在周二的研究报告中开始覆盖 CVS Health 的股票。他们对该股票设定了 “买入” 评级和 91.00 美元的目标价。瑞穗 (Mizuho) 在 10 月 9 日星期四的研究报告中将 CVS Health 的目标价从 76.00 美元上调至 88.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，Leerink Partners 在周四的研究报告中将 CVS Health 的目标价从 86.00 美元上调至 95.00 美元，并给予该股票 “跑赢大盘” 的评级。两位分析师对该股票给予了强买评级，二十位分析师给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat.com 的数据，CVS Health 的共识评级为 “适度买入”，平均目标价为 82.57 美元。</p>
<p><strong>查看我们关于 CVS Health 的最新研究报告</strong></p>
<h2>关于 CVS Health</h2>
<p>(免费报告)</p>
<p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康部门运营。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而非 CVS Health</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>强生的并购策略才是投资者真正需要关注的故事</li>
<li>什么是认沽期权成交量？</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌了吗？</li>
<li>股票交易：相对强弱指数（RSI）及其用途</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 到 CVS Health 吗？</h2>
<p>在考虑 CVS Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 CVS Health 并不在名单上。</p>
<p>虽然 CVS Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西维斯

<p>Kanawha Capital Management LLC 在第二季度收购了 CVS Health Corporation 的新股份，购买了 3,128 股，价值约为 216,000 美元。其他机构投资者，包括先锋集团和道奇与考克斯，也增加了他们在 CVS Health 的持股。该公司报告了强劲的季度收益，收入为 989.2 亿美元，每股收益为 1.81 美元，超出预期。CVS Health 宣布每股季度分红为 0.665 美元，收益率为 3.2%</p>

<p>Kanawha Capital Management LLC purchased a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,128 shares of the pharmacy operator's stock, valued at approximately $216,000.</p>
<div class="lb-trans"><p>Kanawha Capital Management LLC 在第二季度购买了 CVS Health Corporation (NYSE:CVS - 免费报告) 的新股份，根据该公司最近向证券交易委员会 (SEC) 提交的 13F 表格。该基金购买了 3,128 股该药房运营商的股票，价值约为 216,000 美元。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 收益增长，股息保持强劲</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock valued at $8,017,223,000 after acquiring an additional 969,027 shares during the period. Dodge &amp; Cox raised its stake in shares of CVS Health by 4.8% during the first quarter. Dodge &amp; Cox now owns 73,459,122 shares of the pharmacy operator's stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Invesco Ltd. raised its stake in shares of CVS Health by 13.2% during the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator's stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of CVS Health by 14.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator's stock valued at $1,037,205,000 after purchasing an additional 1,942,886 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of CVS Health by 5.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock valued at $924,643,000 after purchasing an additional 728,924 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也调整了对该公司的持股。先锋集团 (Vanguard Group Inc.) 在第一季度将其在 CVS Health 的持股增加了 0.8%。先锋集团目前拥有 118,335,394 股该药房运营商的股票，价值 80.17223 亿美元，在此期间又增持了 969,027 股。道奇与考克斯 (Dodge &amp; Cox) 在第一季度将其在 CVS Health 的持股增加了 4.8%。道奇与考克斯目前拥有 73,459,122 股该药房运营商的股票，价值 49.76856 亿美元，在上个季度又购买了 3,353,223 股。景顺 (Invesco Ltd.) 在第一季度将其在 CVS Health 的持股增加了 13.2%。景顺目前拥有 20,413,853 股该药房运营商的股票，价值 13.83039 亿美元，在上个季度又购买了 2,375,764 股。普莱斯·T·罗威 (Price T Rowe Associates Inc. MD) 在第一季度将其在 CVS Health 的持股增加了 14.5%。普莱斯·T·罗威目前拥有 15,309,289 股该药房运营商的股票，价值 10.37205 亿美元，在上个季度又购买了 1,942,886 股。最后，查尔斯·施瓦布投资管理公司 (Charles Schwab Investment Management Inc.) 在第一季度将其在 CVS Health 的持股增加了 5.6%。查尔斯·施瓦布投资管理公司目前拥有 13,647,873 股该药房运营商的股票，价值 9.24643 亿美元，在上个季度又购买了 728,924 股。机构投资者和对冲基金持有该公司 80.66% 的股份。</p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 股价表现</h2>
</div><p>Shares of CVS Health stock opened at $82.64 on Friday. The company's 50-day moving average price is $74.00 and its two-hundred day moving average price is $68.12. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock has a market cap of $104.81 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $82.88.</p>
<div class="lb-trans"><p>CVS Health 股票周五开盘价为 82.64 美元。该公司的 50 日移动平均价格为 74.00 美元，200 日移动平均价格为 68.12 美元。该公司的流动比率为 0.80，速动比率为 0.62，债务与股本比率为 0.74。该股票的市值为 1048.1 亿美元，市盈率为 23.08，市盈增长比率为 0.91，贝塔值为 0.60。CVS Health Corporation 的 52 周低点为 43.56 美元，52 周高点为 82.88 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 05/12 - 05/16</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health (NYSE:CVS - 获取免费报告) 最近在 7 月 31 日星期四发布了季度财报。该药房运营商报告每股收益 (EPS) 为 1.81 美元，超出市场共识预期的 1.46 美元，超出 0.35 美元。该公司本季度的收入为 989.2 亿美元，而市场共识预期为 948.7 亿美元。CVS Health 的股本回报率为 10.51%，净利润率为 1.17%。该公司本季度的收入较去年同期增长了 8.4%。在去年同期，该公司每股收益为 1.83 美元。CVS Health 将其 2025 财年的指引设定为 6.300-6.400 每股收益。作为一个整体，卖方分析师预计 CVS Health Corporation 本财年将发布 5.89 每股收益。</p>
</div><h2>CVS Health Announces Dividend</h2>
<div class="lb-trans"><h2>CVS Health 宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is presently 74.30%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，将于 11 月 3 日星期一支付。10 月 23 日星期四的股东将获得每股 0.665 美元的分红。这代表着每年 2.66 美元的分红和 3.2% 的收益率。除息日为 10 月 23 日星期四。CVS Health 的派息比率目前为 74.30%。</p>
</div><h2>Insider Transactions at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 内部交易</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是买入诺和诺德股票的时机吗？</li>
</ul>
</div><p>In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 1.22% of the company's stock.</p>
<div class="lb-trans"><p>在其他 CVS Health 的新闻中，董事安妮·A·芬纽肯 (Anne A. Finucane) 在 8 月 20 日星期三出售了 7,500 股该公司的股票。该股票以平均价格 71.02 美元出售，总交易额为 532,650.00 美元。出售后，该董事在公司中持有 22,156 股，价值约为 1,573,519.12 美元。此次交易使其持股减少了 25.29%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有该公司 1.22% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities research analysts recently weighed in on the stock. Zacks Research cut shares of CVS Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, September 8th. Robert W. Baird upgraded shares of CVS Health from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and lifted their price objective for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. The Goldman Sachs Group assumed coverage on shares of CVS Health in a research note on Tuesday. They set a &#34;buy&#34; rating and a $91.00 price objective on the stock. Mizuho boosted their price target on shares of CVS Health from $76.00 to $88.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, October 9th. Finally, Leerink Partners boosted their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $82.57.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发表了看法。扎克斯研究 (Zacks Research) 在 9 月 8 日星期一的研究报告中将 CVS Health 的股票评级从 “强买” 下调至 “持有”。罗伯特·W·贝尔德 (Robert W. Baird) 在 8 月 14 日星期四的研究报告中将 CVS Health 的股票评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标价从 71.00 美元上调至 82.00 美元。高盛集团 (Goldman Sachs Group) 在周二的研究报告中开始覆盖 CVS Health 的股票。他们对该股票设定了 “买入” 评级和 91.00 美元的目标价。瑞穗 (Mizuho) 在 10 月 9 日星期四的研究报告中将 CVS Health 的目标价从 76.00 美元上调至 88.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，Leerink Partners 在周四的研究报告中将 CVS Health 的目标价从 86.00 美元上调至 95.00 美元，并给予该股票 “跑赢大盘” 的评级。两位分析师对该股票给予了强买评级，二十位分析师给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat.com 的数据，CVS Health 的共识评级为 “适度买入”，平均目标价为 82.57 美元。</p>
</div><p><strong>View Our Latest Research Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CVS Health 的最新研究报告</strong></p>
</div><h2>About CVS Health</h2>
<div class="lb-trans"><h2>关于 CVS Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康部门运营。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>What is Put Option Volume?</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 CVS Health</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>强生的并购策略才是投资者真正需要关注的故事</li>
<li>什么是认沽期权成交量？</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌了吗？</li>
<li>股票交易：相对强弱指数（RSI）及其用途</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 到 CVS Health 吗？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CVS Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 CVS Health 并不在名单上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CVS Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kanawha Capital Management LLC 在 CVS Health Corporation 持有 21.6 万美元的头寸